Spiro-lactam NMDA receptor modulators and uses thereof

A method of treating depression, Alzheimer's disease, attention deficit disorder, schizophrenia, anxiety, acute neuropathic pain, or chronic neuropathic pain in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound represented by:

• or a pharmaceutically acceptable salt and/or a stereoisomer thereof, wherein:
• R1 is selected from the group consisting of C1-C6alkyl, phenyl,
• wherein C1-C6 alkyl is substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, hydroxyl, S(O)w—C1-C3alkyl, SH, phenyl and halogen, and wherein phenyl is substituted by one, two or three substituents independently selected for each occurrence from —C(O)—C1-C3alkyl, hydroxyl, —C(O)— C1-C3alkyl, methyl, CF3 and halogen;
• R7 is independently selected from the group consisting of H, —C1-C6alkyl, —S(O)w—C1-C3alkyl, and halogen;
• R9 is independently selected from the group consisting of H, —C1-C6alkyl, —S(O)w—C1-C3alkyl, and halogen, or one R7 and one R9 taken together with the adjacent carbons to which they are attached form a 3-membered carbocyclic ring which can be optionally substituted by one or two substituents independently selected from the group consisting of halogen, hydroxyl, —C1-C3alkyl, —C1-C3alkoxy, —C(O)NRaRb, and —NRaRb;
• R2 is independently selected for each occurrence from the group consisting of H, C1-C6alkyl, —S(O)w—C1-C3alkyl, —NRaRb and halogen;
• R6 represents one or two optional substitutions each on one or more available ring carbons, and is independently selected for each occurrence from the group consisting of C1-C6alkyl, —S(O)w—C1-C3alkyl, —NRaRb and halogen;
• w is 0, 1, or 2;
• R3 is selected from the group consisting of H, C1-C6 alkyl, —C(O)R31 and —C(O)OR32;
• R31 and R32 are each independently selected from the group consisting of H, C1-C6alkyl, —C3-C6cycloalkyl, and phenyl;
• and
• Ra and Rb are each independently for each occurrence selected from the group consisting of H, phenyl, and C1-C3alkyl, or Ra and Rb taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;
• wherein any aforementioned C1-C6 alkyl of R2, R3, R5, R6 R7, R9, R31 and R32, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, hydroxyl, S(O)w—C1-C3alkyl, SH, phenyl and halogen, and any aforementioned phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)—C1-C3alkyl, hydroxyl, methyl, CF3 and halogen.